Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the percentage of people who can attain remission
and the length of time such responses to therapy are sustained, as well as the side effects
that might result from rituximab and thalidomide in people with lymphoplasmacytic lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Steven P. Treon, MD, PhD
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Cape Cod Healthcare Cape Cod Hospital Dana-Farber Cancer Institute Massachusetts General Hospital